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2 |   A SURVEY ON MP IN LIVER TRANSPLANTATION
1 |  INTRODUCTION
Machine	 perfusion	 (MP)	 is	 revolutionizing	 the	 field	 of	
liver	 transplantation	 (LT).1,2	 The	 deep	 interest	 in	 MP,	 a	
term	that	encompasses	various	approaches,	 is	supported	
by	the	 impelling	necessity	to	 increase	donor	pool	and	to	
improve	 the	 preservation	 of	 grafts	 from	 extended	 crite-
ria	donors.	This	necessity	fostered	its	transition	from	the	





In	 keeping	 with	 the	 relatively	 recent	 adoption,	 MP	
indications	 and	 modality	 appear	 to	 be	 highly	 variable	
















metastases	even	among	experts	 in	 the	 field.25	The	work-
ing	hypothesis	of	this	survey	was	that	indications	for	MP	
are	 heterogeneous,	 even	 among	 transplant	 professionals	
with	direct	MP	experience	and	a	thorough	understanding	
of	the	advantages	and	limitations	of	each	technique.	This	
survey	 aimed	 to	 provide	 an	 accurate	 and	 representative	
cross-	sectional	picture	of	how	different	MP	modalities	are	
perceived	among	various	groups	and	regions,	 to	 identify	
the	specific	areas	of	 interest	 for	 future	consensus	guide-
lines	and	highlight	the	issues	and	needs	of	transplant	pro-
fessionals	toward	MP	technology.
2 |  MATERIALS AND METHODS
A	 web-	based	 Google	 Forms	 survey	 (https://forms.











ommendations	 “Best	 Practices	 for	 Survey	 Research”	 by	




at	 each	 stage.	 For	 stratification	 purposes,	 geographical	
location,	 volume	 and	 presence	 of	 an	 established	 MP	
program	at	respondent	center	was	asked	in	preliminary	
questions.	 Noteworthy,	 also	 respondents	 from	 centers	
without	 an	 established	 MP	 program	 had	 direct	 clinical	






is	 available	 as	 Supporting	 Information.	 All	 participants	
included	as	co-	authors	accepted	to	be	 included	and	ap-
proved	 the	 final	 version	 of	 the	 manuscript.	The	 survey	
was	 approved	 by	 the	 local	 Institutional	 Review	 Board	











histologic	 features	 like	 degree	 of	 macrovesicular	 steato-
sis.	 A	 brief	 picture	 of	 recipient	 clinical	 data	 and	 degree	
of	urgency	was	also	provided,	 to	allow	respondents	also	
answering	on	the	ground	of	donor–	recipient	matching.
Cases	 were	 chosen	 to	 reflect	 the	 heterogeneity	
of	 scenarios	 that	 may	 be	 faced	 in	 everyday	 practice.	
Particularly,	three	cases	(cases	1,	7,	and	10)	were	charac-
terized	by	advanced	donor	age	(>75 years).	Of	these,	one	
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and	 underwent	 normothermic	 regional	 perfusion	 prior	





For	 each	 case,	 respondents	 were	 asked	 whether	 they	
would	accept	the	offer	(Q1),	whether	they	would	use	MP	
(Q2)	and,	 if	 so,	which	modality	 they	would	choose	 (Q3)	
and	at	what	timing	during	preservation	(Q4).	A	free	com-
ment	could	be	added	at	the	end	of	each	case	(Q5).
MP	 techniques	 were	 defined	 according	 to	 standard	
definitions.26	 A	 sequential	 approach	 was	 defined	 as	 hy-
pothermic	 MP	 followed	 by	 normothermic	 MP,	 with	 or	








Data	 are	 expressed	 as	 number	 (%)	 and	 median	 (in-






can	 be	 expected	 by	 chance).	 A	 value	 of	 0	 reflects	 no	 in-
terrater	 agreement	 beyond	 casual	 agreement	 by	 chance.	
Alpha	 >	 0.8	 is	 generally	 accepted	 as	 a	 measure	 of	 good	
interrater	 agreement.	 Statistical	 analyses	 and	 data	 visu-
alization	 were	 performed	 using	 R:	 A	 language	 and	 en-
vironment	 for	 statistical	 computing	 (R	 Foundation	 for	
Statistical	Computing,	Vienna,	Austria).
3 |  RESULTS
Response	 rate	 was	 30.1%	 (39/127).	 Of	 respondents,	
10	 were	 senior	 figures	 or	 program	 directors	 at	 their	
Institution.	 Most	 respondents	 were	 from	 Europe	
(n = 35,	89.7%),	whereas	3	(7.7%)	and	1	(2.6%)	were	from	
T A B L E  1  Brief	description	of	survey	cases	(for	a	full	description	see	Supporting	Information)
Donor issues Recipient issues MP1 Transplanted Outcome
Case	1 78-	yo	DBD	with	20%	
macrosteatosis











MELD	=	21 NRP	+	D-	HOPE Yes Alive	at	12 months;	no	ITBL
Case	4 56-	yo	type	III	DCD	with	
49-	minutes	fWIT
None NRP	+	D-	HOPE Yes Alive	at	10 months;	no	ITBL
Case	5 52-	yo	DBD	with	elevated	liver	
enzymes
None D-	HOPE Yes Alive	at	14 months;	no	ITBL
Case	6 42-	yo	DBD	with	steatotic	
appearance














None NRP	+	NMP No Na
Case	
10
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North	America	and	South	America,	respectively.	Centre	
volume	 was	 ≥100,	 50-	100,	 and	 <50	 for	 10	 (25.6%),	 19	
(48.7%),	and	10	 (25.6%)	respondents,	 respectively.	Five	
respondents	 were	 from	 centers	 without	 an	 established	
MP	program.
Figures  1	 and	 2	 summarize	 participants’	 choices	 in	
each	 case,	 highlighting	 significant	 heterogeneity	 toward	
MP	 indication,	 modality,	 and	 graft	 acceptance.	 Lack	 of	
agreement	between	participants	was	confirmed	by	inter-
rater	 reliability	 analysis,	 which	 showed	 Krippendorff 's	
alpha	coefficient	never	exceeding	0.15	for	any	of	the	sur-







cated	174	 times	 (44.6%).	Hypothermic	MP	was	 the	most	
preferred	approach	in	98	(56.3%)	cases,	 followed	by	nor-
mothermic	 (n  =  63,	 36.2%),	 sequential	 (n  =  10,	 5.7%),	
and	subnormothermic	MP	(n = 3,	1.7%).	One	participant	
(2.6%)	 did	 not	 consider	 MP	 useful	 in	 any	 case,	 whereas	
18	(46.2%),	17	(43.6%),	and	3	(7.7%)	considered	one,	two,	
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was	 preferred	 in	 137	 (81.1%)	 cases,	 whereas	 continu-
ous	 perfusion	 throughout	 preservation	 was	 chosen	 in	
32	 (18.9%).	 In	 five	 cases,	 preferred	 timing	 was	 not	 in-















4 |  DISCUSSION
The	results	of	 this	survey	could	be	summarized	 in	 three	
main	points.	First,	there	were	significant	discrepancies	in	










MP	 indications	 and	 techniques	 are	 strongly	 varying,	
which	 can	 be	 attributed	 to	 the	 very	 recent	 clinical	 rein-
troduction	 of	 this	 technology	 after	 the	 early	 experiences	
in	 the	 pioneering	 era	 of	 solid	 organ	 transplantation.27	 As	
of	 today,	 three	 randomized	 controlled	 trials	 have	 been	
published,9,11,19	one	of	which	after	 the	completion	of	 this	
survey.19	 Along	 with	 other	 retrospective	 studies,	 current	
literature	suggests	that	MP	conveys	a	significant	advantage	
over	static	cold	storage	in	several	settings,	 including	DCD	
donors,7,15,18,19	 extended-	criteria	 DBD	 donors,12,14	 elderly	
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T A B L E  2  Agreement	between	respondents	according	to	setting	and	complexity	of	cases
All cases Age > 75 Steatotic DCD Low complexity High complexity
Q1:	graft	acceptance
PA 69% 70% 73% 62% 77% 68%
α 0.11 −0.01 0.02 0.17 −0.01 0.12
CI (−0.05,	0.27) (−0.03,	0.02) (−0.10,	0.14) (−0.27,	0.62) (−0.02,	0.01) (−0.05,	0.29)
Q2:	use	of	MP	(yes/no)
PA 45% 38% 43% 51% 50% 44%
α 0.14 −0.01 0.09 0.11 0.01 0.09
CI (0.04,	0.25) (−0.02,	0.01) (0.07,	0.12) (−0.15,	0.37) (−0.04,	0.07) (−0.01,	0.20)
Q3:	MP	preferred	approach
PA 33% 26% 32% 34% 46% 30%
α 0.11 −0.01 0.06 0.09 0.01 0.08
CI (0.02,	0.20) (−0.02,	0.01) (−0.05,	0.18) (−0.11,	0.30) (−0.04,	0.05) (−0.01,	0.16)
Q4:	Timing	of	MP
PA 38% 30% 37% 41% 50% 35%
α 0.12 −0.01 0.08 0.09 0.01 0.08












Hypothermic 98	(56.3) 12	(63.2) 86	(55.5)
Normothermic 63	(36.2) 3	(15.8) 60	(38.7)
Sequential	approach 10	(5.7) 1	(5.3) 9	(5.8)
Subnormothermic 3	(1.7) 3	(15.8) 0	(0.0)
Note: Data	are	presented	as	number	(%).
*Chi-	square	test	comparing	group	with	and	without	an	established	MP	program.














T A B L E  4  Timing	of	machine	
perfusion	according	to	technique











As	 expected,	 the	 choice	 of	 MP	 technique	 was	 arbi-
trary,	 subjective,	 or	 center-	related.	 Indeed,	 early	 studies	
have	 assessed	 feasibility	 of	 MP	 in	 a	 clinical	 setting	 or	
compared	 MP	 with	 SCS.	 No	 study	 comparing	 different	
MP	techniques	head-	to-	head	has	been	published	so	far.28	
However,	results	of	a	large,	multicenter	study	comparing	






preferred	 timing	 (81.1%	 of	 cases).	The	 reason	 why	 most	
respondents	 tended	 to	 prefer	 hypothermic	 MP	 might	 be	
at	least	partially	related	to	the	fact	that	hypothermic	MP	
is	 frequently	 perceived	 as	 technically	 easier	 to	 perform	
and	 associated	 with	 inferior	 technology-	related	 risks.	





tical	 challenges	 linked	 to	 backtable	 preparation	 and	 MP	
setup	 at	 the	 retrieval	 hospital	 and	 the	 risks	 associated	
with	potential	device	malfunction	during	organ	transport.	







pected	 that	 most	 respondents	 would	 feel	 more	 comfort-
able	with	one	particular	technique.	In	contrast,	half	of	the	
respondents	chose	at	least	two	different	techniques	for	the	
proposed	 scenarios,	 suggesting	 that	 different	 techniques	














survey,	 viability	 assessment	 were	 invariably	 associated	
with	the	use	of	normothermic	MP.	However,	as	brilliantly	
summarized	 by	 Brüggenwirth	 et	 al,34,35	 viability	 assess-
ment	 is	 still	 an	 imperfect	 science,	 as	many	criteria	have	
been	 proposed	 but	 none	 validated.	 Many	 criteria	 focus	
on	 hepatocyte	 function,	 whereas	 cholangiocyte	 function	
and	 injury	 have	 been	 rather	 neglected.2,36	 Furthermore,	
some	 promising	 findings	 from	 the	 Zurich	 group	 suggest	
that	viability	assessment	is	possible	also	during	hypother-
mic	MP,	although	validation	of	this	claim	is	still	lacking.37	







light	 the	 urgent	 need	 for	 more	 clinical	 data	 and	 studies	
to	 make	 an	 evidence-	based	 approach	 to	 MP	 utilization	
possible.	The	recently	released	ILTS	consensus	guidelines	
on	ex	 situ	 liver	MP	have	addressed	 relevant	aspects	and	








This	 study	has	 limitations,	 including	 limited	sample	
size	 (n  =  39)	 and	 response	 rate	 (30.1%),	 although	 this	
last	was	in	line	with	that	of	other	web-	based	medical	sur-
veys.41	As	the	majority	of	participants	were	from	Europe,	
results	 do	 not	 accurately	 reflect	 practices	 elsewhere.	
Significant	differences	in	donation	rate,	waiting	list	time,	
surgeons	 personal	 experience	 and	 country-	specific	 pro-
tocols,	especially	with	regards	to	DCD	donors	(systematic	
use	of	end-	ischemic	hypothermic	MP	vs.	normothermic	
regional	 perfusion),	 could	 have	 influenced	 variance	 in	
answers.	As	an	example,	use	of	normothermic	regional	
perfusion	 in	 the	 proposed	 DCD	 cases	 was	 obligatory	 at	
the	promoting	center,	and	this	is	why	this	was	not	con-
sidered	 as	 a	 further	 preservation	 option.	 However,	 nor-
mothermic	 regional	 perfusion	 undoubtedly	 represents	
another	variable	in	the	equation	and	its	use,	alone	or	in	
association	 with	 MP,	 certainly	 deserves	 evaluation.8,42	
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One	strength	of	this	survey	was	its	being	targeted	to	peo-
ple	with	direct	hands-	on	experience	with	MP	and	with	a	
solid	 background	 about	 the	 advantages	 and	 limitations	
of	each	technique.
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APPENDIX A
The Liver Machine Perfusion Survey Group:	Roberta	
Angelico	 (HPB	 and	 Transplant	 Unit,	 Department	 of	
Surgery	 Science,	 Tor	 Vergata	 University,	 Rome,	 Italy);	
Maria	Irene	Bellini	(Department	of	Emergency	Medicine	
and	Surgery,	Azienda	Ospedaliera	San	Camillo	Forlanini,	
Rome,	 Italy;	 Department	 of	 Surgical	 Sciences,	 Sapienza	
Università	 di	 Roma,	 Rome,	 Italy);	 Eliano	 Bonaccorsi-	
Riani	 (Starzl	 Unit	 of	 Abdominal	 Transplantation,	
Cliniques	Universitaires	Saint-	Luc,	Université	catholique	
de	 Louvain,	 Brussels,	 Belgium;	 Pôle	 de	 Chirurgie	
Expérimentale	et	Transplantation,	Université	Catholique	
de	Louvain,	Brussels,	Belgium);	Isabel	M.	A.	Brüggenwirth	
(Department	 of	 Surgery,	 University	 of	 Groningen,	
University	 Medical	 Center	 Groningen,	 Groningen,	 The	
Netherlands);	 Zoltan	 Czigany	 (Department	 of	 Surgery	
and	Transplantation,	University	Hospital	RWTH	Aachen,	
Aachen,	 Germany);	 Riccardo	 De	 Carlis	 (Department	
of	 General	 Surgery	 and	 Transplantation,	 ASST	 Grande	
Ospedale	Metropolitano	Niguarda,	Milan,	Italy);	Vincent	
E.	 De	 Meijer	 (Department	 of	 Surgery,	 University	 of	
Groningen,	 University	 Medical	 Center	 Groningen,	
Groningen,	 The	 Netherlands);	 Daniele	 Dondossola	
(General	and	Liver	Transplant	Surgery	Unit,	Fondazione	
IRCCS	 Ca'	 Granda	 Ospedale	 Maggiore	 Policlinico,	
Milan,	Italy);	Dilmurodjon	Eshmuminov	(Department	of	




Italy);	 Amelia	 J.	 Hessheimer	 (Hepatopancreatobiliary	
Surgery	 &	 Transplantation,	 Hospital	 Clínic	 Barcelona,	
IDIBAPS,	CIBERehd,	University	of	Barcelona,	Barcelona,	
Spain);	 Dagmar	 Kollmann	 (Department	 of	 Surgery,	




Italy);	 Georg	 Lurje	 (Department	 of	 Surgery,	 Campus	
Charité	 Mitte,	 Campus	 Virchow-	Klinikum,	 Charité-	
Universitätsmedizin	Berlin,	Berlin,	Germany);	Tommaso	
M.	 Manzia	 (HPB	 and	 Transplant	 Unit,	 Department	 of	
Surgery	 Science,	 Tor	 Vergata	 University,	 Rome,	 Italy);	
Arianeb	 Merhabi	 (Department	 of	 General,	 Abdominal	
and	 Transplant	 Surgery,	 Ruprecht-	Karls	 University	 of	
Heidelberg,	 Heidelberg,	 Germany);	 Fabio	 Melandro	
(Division	 of	 Hepatic	 Surgery	 and	 Liver	 transplantation,	
University	 Hospital	 of	 Pisa,	 Pisa,	 Italy);	 David	 Nasralla	
(Department	of	HPB	&	Liver	Transplant	Surgery,	Royal	Free	
Hospital,	 London,	 UK);	 Arash	 Nickkholgh	 (Department	
of	General,	Abdominal	and	Transplant	Surgery,	Ruprecht-	
Karls	 University	 of	 Heidelberg,	 Heidelberg,	 Germany);	
Duilio	Pagano	(Department	for	the	Treatment	and	Study	
of	Abdominal	Diseases	and	Abdominal	Transplantation,	
IRCCS-	ISMETT,	 UPMC	 Italy,	 Palermo,	 Italy);	 Michel	
Rayar	(CHU	Rennes,	Service	de	Chirurgie	Hépatobiliaire	
et	 Digestive,	 F-	35033	 Rennes,	 France);	 Maria	 Cristina	
Saffioti	 (Division	 of	 Hepatobiliopancreatic	 Surgery,	
Liver	 and	 Kidney	 Transplantation,	 Research	 Unit	 of	
Clinical	 Hepatogastroenterology	 and	 Transplantation,	
Bambino	 Gesù	 Children's	 Hospital,	 IRCCS,	 Piazza	
Sant'Onofrio,	4,	Rome,	Italy);	Annemarie	Weissenbacher	
(Department	 of	 Visceral,	 Transplant	 and	 Thoracic	
Surgery,	 Medical	 University	 of	 Innsbruck,	 Innsbruck,	
Austria);	 Alfonso	 W.	 Avolio	 (General	 Surgery	 and	
Liver	 Transplantation	 Unit,	 Fondazione	 Policlinico	
Universitario	 Agostino	 Gemelli,	 IRCCS,	 Rome,	 Italy);	
Paolo	De	Simone	(Division	of	Hepatic	Surgery	and	Liver	
transplantation,	 University	 Hospital	 of	 Pisa,	 Pisa,	 Italy);	
Costantino	 Fondevila	 (Hepatopancreatobiliary	 Surgery	
&	 Transplantation,	 Hospital	 Clínic	 Barcelona,	 IDIBAPS,	
CIBERehd,	 University	 of	 Barcelona,	 Barcelona,	 Spain);	
Wayel	 Jassem	 (Institute	 of	 Liver	 Studies,	 King’s	 College	
Hospital,	 SE5	 9RS	 London,	 UK);	 Malcolm	 Macconmara	
(Surgery,	 Solid	 Organ	 Transplant	 Program,	 UT	
Southwestern	Medical	Center,	Dallas,	TX,	USA);	Robert	
J.	Porte	(Department	of	Surgery,	University	of	Groningen,	
University	 Medical	 Center	 Groningen,	 Groningen,	
The	 Netherlands);	 Matteo	 Ravaioli	 (Department	 of	
Medical	 and	 Surgical	 Sciences	 (DIMEC),	 University	 of	
Bologna,	Bologna,	 Italy;	Department	of	General	Surgery	
and	 Transplantation,	 IRCCS,	 Azienda	 Ospedaliero-	
Universitaria	 di	 Bologna,	 Bologna,	 Italy);	 Markus	
Selzner	 (Multi	 Organ	 Transplant	 Program,	 Department	
of	 Surgery,	 Toronto	 General	 Hospital,	 Canada);	 Marco	
Spada	 (Division	 of	 Hepatobiliopancreatic	 Surgery,	 Liver	
and	 Kidney	 Transplantation,	 Research	 Unit	 of	 Clinical	
Hepatogastroenterology	 and	 Transplantation,	 Bambino	
Gesù	Children's	Hospital,	IRCCS,	Piazza	Sant'Onofrio,	4,	
Rome,	Italy).
